Dr. Mark E. Borowsky, MD
Gynecologic Oncology (Gynecologic Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 33
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 136
Licensed in Delaware since 1997, according to the Delaware Division of Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
DE license C10005136 (first issued 1997; expired)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Jersey Shore University Medical Center Neptune, NJ
- Jfk University Medical Center Edison, NJ
- Ocean Medical Center Brick, NJ
- Riverview Medical Center Red Bank, NJ
- Southern Ocean Medical Center Manahawkin, NJ
Medical groups
- Hackensack Meridian Health Medical Group - Specialty Care PC (1,922 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 136
- Services billed
- 391
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 72 | 49 |
| Established patient office or other outpatient visit, 30-39 minutes | 50 | 36 |
| Established patient office or other outpatient visit, 40-54 minutes | 39 | 20 |
| New patient office or other outpatient visit, 45-59 minutes | 34 | 34 |
| New patient office or other outpatient visit, 30-44 minutes | 17 | 17 |
| New patient office or other outpatient visit, 60-74 minutes | 16 | 16 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 5 companies reported 11 payments worth $201 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $55.07 |
|---|---|
| AbbVie Inc. | $48.65 |
| Merck Sharp & Dohme LLC | $43.42 |
| GlaxoSmithKline, LLC. | $36.53 |
| Eisai Inc. | $17.33 |
| Food and Beverage | $201 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $27,650 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Karyopharm Therapeutics Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.